Thursday 4 June 2009
OncoGenex Pharmaceuticals Inc, having demonstrated that its experimental prostate cancer drug extends survival by nearly seven months, is now focused on finding a partner to develop the drug.
>> http://www.reuters.com/article/healthNews/idUSTRE54U1NA20090531
Recent stories
Most people told to get a colonoscopy don't
>> Find out more
Ten biomarkers for lung cancer detection
>> Find out more
Diesel exhaust linked to lung cancer deaths
>> Find out more
Identify depressive symptoms early in breast cancer patients
>> Find out more
Antibiotics may help gastric DLBCL patients avoid chemo
>> Find out more
Risk of fatal adverse events in VEGF-targeting cancer drugs
>> Find out more
Vitamin E supplements linked to prostate cancer risk
>> Find out more
Aspirin: cancer prevention benefits outweigh risks for 55-75 age group
>> Find out more
How does prenatal chemotherapy exposure affect children?
>> Find out more
Colonoscopy with adenoma removal cut colorectal cancer deaths by 53%
>> Find out more
Faecal immunochemical test not good at finding adenomas
>> Find out more
Less intensive monitoring does not jeopardise melanoma care
>> Find out more
MDV3100 cuts risk of death in advanced prostate cancer
>> Find out more
We should no longer think of NSCLC as a single disease
>> Find out more
Arthritis drugs do not increase cancer risk, study suggests
>> Find out more
Link between ADT and cardiovascular death not found
>> Find out more
Vitamin D/breast cancer link questioned
>> Find out more
Acupuncture proves ineffective as pain relief
>> Find out more
Is personalised medicine the future for pancreatic cancer treatment?
>> Find out more
Left-sided radiotherapy linked to cardiovascular stenosis
>> Find out more